Former Nebraska Sen. Ben Sasse announced that his Stage 4 pancreatic cancer tumors have shrunk by over 80% after six and a half months on an experimental drug called daraxonrasib. Sasse, who was initially given three to four months to live in December 2025, credited the oral therapy—designed to block a defective gene triggering uncontrolled cellular growth—as a key factor in his improved prognosis. He also highlighted the role of his faith in his health journey.
Sasse shared his latest health update in a pre-recorded interview for the Western Conservative Summit in Lakewood, Colorado, exclusively provided to Fox News Digital. He noted that as of his latest update, he was nearly seven months past his original prognosis, describing the drug’s impact as "amazing."
Sasse’s Warning on America’s Future
Despite his personal health progress, Sasse expressed growing pessimism about the United States’ trajectory, emphasizing concerns over economic competition with China, the state of U.S. education, and the nation’s ability to adapt to an AI-driven economy. He argued that America must outcompete China to maintain global influence, stating in the interview that he hopes the U.S. will lead the world rather than a "tyrannical, Maoist" China.
Sasse, 54, was diagnosed with metastatic pancreatic cancer, which had spread to his liver and lungs at the time of his initial prognosis. His treatment with daraxonrasib represents an off-label use of the drug, which is still under clinical investigation.
Context on Pancreatic Cancer and Treatment
Pancreatic cancer remains one of the deadliest forms of cancer, with a five-year survival rate of approximately 12% in the U.S. according to the American Cancer Society. The disease is often diagnosed at advanced stages, limiting treatment options. Clinical trials like the one Sasse is participating in are critical for advancing potential therapies.
While Sasse’s tumor reduction is a positive development, medical experts caution that individual responses to experimental treatments vary widely, and long-term outcomes remain uncertain. The drug daraxonrasib, developed by RasCal Therapeutics, targets the KRAS G12D mutation, a common genetic driver in pancreatic cancer.
Reaction to Sasse’s Update
Sasse’s health update has drawn attention from both medical professionals and political observers. Some health advocates have praised his transparency, noting that public figures sharing personal health struggles can raise awareness about underfunded diseases like pancreatic cancer. Others have focused on his political commentary, interpreting his remarks as a call for greater U.S. investment in technology and education to counter China’s rising influence.
Sasse, a former Republican senator known for his conservative-leaning policy positions, did not tie his health update to any specific political agenda but framed his concerns as a broader national challenge. His comments on China’s global ambitions reflect ongoing debates in Washington about economic competitiveness and technological sovereignty.
Ongoing Developments
The clinical trial for daraxonrasib remains active, with researchers monitoring participants for long-term efficacy and side effects. Separately, early-stage research into pancreatic cancer vaccines has shown promise in preventing disease progression in high-risk patients, though these treatments are not yet widely available.
Sasse’s case underscores the urgency of advancing cancer research, particularly for diseases with historically low survival rates. His update also highlights the intersection of personal health and national policy, as policymakers grapple with how to position the U.S. for future economic and technological leadership.